2024
HIV and Substance Use Disorders
Lier A, Tarfa A, Shenoi S, Kuo I, Springer S. HIV and Substance Use Disorders. Infectious Disease Clinics Of North America 2024, 38: 599-611. PMID: 38960783, PMCID: PMC11410345, DOI: 10.1016/j.idc.2024.06.003.Peer-Reviewed Original ResearchHuman immunodeficiency virusSubstance use disordersEvidence-based public health effortsHuman immunodeficiency virus acquisitionHuman immunodeficiency virus incidenceRisk of HIV acquisitionUntreated substance use disordersPoor HIV outcomesAdherence to HIV antiretroviral therapyHIV antiretroviral therapyPublic health effortsInjection drug useAntiretroviral therapyHIV acquisitionImmunodeficiency virusHIV outcomesHealth effortsTreatment strategiesIncreased riskDrug useSubstance useDrugAmericanRiskPersonsHIV Risk and Interest in Preexposure Prophylaxis in Justice-Involved Persons - Volume 30, Supplement—March 2024 - Emerging Infectious Diseases journal - CDC
Nijhawan A, Pulitzer Z, Torres B, Noreen N, Schultheis A, Frank C, Colon R, Brooks R, Proffitt R, Pankow J, Bennett A, Salyards M, Kuo I, Knight K, Springer S. HIV Risk and Interest in Preexposure Prophylaxis in Justice-Involved Persons - Volume 30, Supplement—March 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: s68-s74. PMID: 38561803, PMCID: PMC10986824, DOI: 10.3201/eid3013.230739.Peer-Reviewed Original ResearchConceptsHIV riskAssess HIV risk factorsPreexposure prophylaxisPartners of unknown HIV statusMobile health unitReport injection drug useUnknown HIV statusPerceived HIV riskRisk factorsHIV risk factorsRandomized controlled trialsPatient navigationPrEP indicationsInjection drug useHealth unitsJustice-involved personsHIV medicationsHIV statusCondomless sexPrEPEducational effortsDrug useHIVRiskPersons
2021
Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder
Biondi BE, Mohanty S, Wyk BV, Montgomery RR, Shaw AC, Springer SA. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. Contemporary Clinical Trials Communications 2021, 21: 100704. PMID: 33490708, PMCID: PMC7807244, DOI: 10.1016/j.conctc.2021.100704.Peer-Reviewed Original ResearchOpioid use disorderProspective cohort studyHIV infectionCohort studyMedication treatmentUse disordersDSM-5 opioid-use disordersLongitudinal studyBiological effectsHIV continuumMonth 6Immune responseDifferential biological effectsMOUDHIVSystems biology approachInfectionTreatmentDSM-5DisordersPersonsBiology approachMedicationsBuprenorphineMethadone
2020
The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic Review
Seval N, Wurcel A, Gunderson CG, Grimshaw A, Springer SA. The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic Review. Infectious Disease Clinics Of North America 2020, 34: 559-584. PMID: 32782102, PMCID: PMC7437982, DOI: 10.1016/j.idc.2020.06.011.Peer-Reviewed Original ResearchLessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid Epidemic
Springer SA, del Rio C. Lessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid Epidemic. Infectious Disease Clinics Of North America 2020, 34: 637-647. PMID: 32782106, PMCID: PMC7414693, DOI: 10.1016/j.idc.2020.06.015.Peer-Reviewed Original Research